This is an amended filing · View original →
KYUNG NAM PHARM.CO.,LTD. Q3 revenue KRW 20.7 billion, operating loss KRW 1.3 billion; revenue up 46.2% from a year earlier
AI summary · Not investment advice
In Q3, the company sold KRW 20.7 billion worth and lost KRW 1.3 billion from its main business; sales rose 46.2% from a year earlier and 16.3% from the prior quarter.
Operating profit · 3 months
KRW -1.3 billion
Key facts
- Revenue (3 months)
- KRW 20.7 billion
- Net income (3 months)
- KRW -2.9 billion
- Period
- Q3 (cumulative 2026.01.01 ~ 2026.09.30)
- Revenue (prior-year 3 months)
- KRW 14.2 billion
- Revenue (year to date)
- KRW 54.6 billion
- Operating profit (prior-year 3 months)
- KRW -1.1 billion
- Operating profit (year to date)
- KRW -1.1 billion
- Net income (prior-year 3 months)
- KRW -4.7 billion
- Net income (year to date)
- KRW -7.2 billion
Commentary
AI commentary · Not investment advice
What happened
Kyungnam Pharm reported its consolidated results for the third quarter. Sales for the latest 3 months were KRW 20.71 billion. That is 46.2% more than the same period a year earlier and 16.3% more than the previous quarter. Cumulative sales this year were KRW 54.65 billion.
In the company's terms
Operating profit (profit from the core business) for the latest 3 months was KRW -1.31 billion. A year earlier it was KRW -1.06 billion. Cumulative operating profit this year was KRW -1.14 billion.
What changes for shareholders
Net income (the final profit after all costs and taxes) for the latest 3 months was KRW -2.89 billion. A year earlier it was KRW -4.68 billion. Cumulative net income this year was KRW -7.15 billion.
Comments
No comments yet
Comments from shareholders will appear here.
Ad
Verify your holdings and catch the next disclosure
Verify the stocks you hold and get new disclosures as app alerts.

App design sample
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist
K